SWTX (SpringWorks Therapeutics Inc.) Earnings per share for the last four quarters

Public company logo of SpringWorks Therapeutics Inc. (SWTX)

Amidst fierce competition with biotech giants for rare pathology niches, SpringWorks Therapeutics (SWTX) EPS dynamics over the last 12 months year-over-year demonstrate business resilience. The metric stands at 5.70, which is supported by the flawless condition of partners' production capacities. Such stability is ensured by the complete non-cyclical nature of demand for targeted therapy, which remains resistant to any economic fluctuations.

SWTX springworkstx.com Earnings per share for the last twelve months (02/11/2024 - 02/20/2024)

SpringWorks - analytical breakdowns and key metrics (SWTX)

- current price and projected stock value:
Price Performance Chart springworkstx.com|SWTX - Consensus Target
- business market valuation indicators:
Market Value SpringWorks Therapeutics Inc.|SWTX - Enterprise Value
- business book valuation details:
Book Value per Share SpringWorks Therapeutics|SWTX - Company Book Value|Market Value to Book Value springworkstx.com|SWTX - Company Total Assets
- company total debt and liquidity indicators:
Debt to Capital Ratio SpringWorks Therapeutics|SWTX - Long-Term Debt to Capital|Current Liabilities to Capital SpringWorks Therapeutics, Inc|SWTX - Company Total Debt|Debt to Book Capital SpringWorks Therapeutics Inc.|SWTX - Company Long-Term Debts|Short-Term Debt SpringWorks Therapeutics|Immediate Liquidity Ratio springworkstx.com
- earnings and multiples data:
SWTX - Net Income|Expected Net Income SpringWorks Therapeutics|SWTX - Price to Earnings Ratio|Market Cap to Future Earnings Ratio SpringWorks Therapeutics Inc.|SWTX - PEG Multiple|Business Value to Operating Income Before Depreciation SpringWorks Therapeutics Inc.|SWTX - Operating profit EBITDA|Net earnings per one share for the last twelve months SpringWorks Therapeutics|SWTX - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months springworkstx.com|SWTX - Earnings growth in current year|Earnings growth forecast for next year SpringWorks Therapeutics
Fundamental valuation:springworkstx.com (SWTX)
Signature product of SpringWorks Therapeutics, Inc.

SpringWorks Therapeutics (SWTX) monopoly in the targeted therapy market for rare tumors creates a foundation for long-term profit growth. This indicator measures the dynamics of net income per share on a rolling year basis, neutralizing the seasonality of quarterly reports. Analyzing growth rates allows for an assessment of capital efficiency relative to the WACC. Ignoring one-time gains may distort the real value of the business. Monitor these trends using the net income per share YoY ttm growth rate chart.

Competitor analysis for SpringWorks Therapeutics

Earnings per share for the trailing year GMAB (genmab.com)|EXEL (Exelixis) - Net earnings per share for the last 12 months|NUVL: Earnings per share for the last four quarters|KYMR (Kymera Therapeutics Inc) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) IDEAYA Corp|Earnings per share for the last twelve months Enliven Therapeutics (ELVN)|ORIC (oricpharma.com) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) RLAY (Relay Therapeutics, Inc.)|Net earnings per share for the trailing year Nurix Therapeutics Inc|Tyra Bio - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Verastem Corp|GLUE (Monte Rosa Therapeutics) - Net earnings per share for the last 12 months|CGEM: Earnings per share for the last four quarters|IMRX (Immuneering) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months C4 Therapeutics Inc CCCC|Net earnings per share (EPS TTM) BDTX|Repare Therapeutics Inc - Earnings per share for the last 12 months|PMV Pharmaceuticals - Net earnings per share for the last 12 months|Earnings per share for the trailing year KPTI|PPCB: Net earnings per share for the last 12 months|Bio Green Med Solution Inc. - Earnings per share for the last four quarters|AADI: Net earnings per share (EPS TTM)|Aileron Therapeutics, Inc. - Earnings per share for the trailing year|BPMC (Blueprint Medicines Corp.) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months GlycoMimetics Corp GLYC